whatshot

KHTRF   $3.65  -0.27% Market Closed

KNIGHT THERAPEUTICS INC
show_chart Advanced Chart of KHTRF
Last Events:

2023-08-02 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-07-18 Trend pattern changed from расходящийся треугольник to сужающийся канал.

2023-07-18 Signal in Stochastic changed from bullish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-07-18 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: exit from the overbought zone.

2023-07-18 Trend Power changed from to medium strength.

2023-05-18 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-05-18 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: entrance to the overbought zone.

2023-04-28 Trend pattern changed from не определен to расходящийся треугольник.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 7
Target Price Mean 6
Mean unverified/preliminary 6 / 6
Target Price Low / High 4 / 7
Median / STD DEV 6 / 0.93
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell None
rsi Sell Sell None
macd None None None
stoch None None None
ma20 Sell None None
ma50 None None None
ma100 None ActivelyBuy None
ISIN CA4990531069
ceo Ms. Samira Sakhia BCom, CA, CPA, MBA
Website https://www.gud-knight.com
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.